{"id":6589,"date":"2024-11-09T12:07:50","date_gmt":"2024-11-09T11:07:50","guid":{"rendered":"https:\/\/alpha1-deutschland.org\/?p=6589"},"modified":"2025-04-28T12:29:09","modified_gmt":"2025-04-28T10:29:09","slug":"neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel","status":"publish","type":"post","link":"https:\/\/alpha1-deutschland.org\/en\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel","title":{"rendered":"New study on liver involvement in alpha1 antitrypsin deficiency published"},"content":{"rendered":"<div id=\"fws_6a8c8eb127539\"  data-column-margin=\"default\" data-midnight=\"dark\"  class=\"wpb_row vc_row-fluid vc_row full-width-section\"  style=\"padding-top: 0px; padding-bottom: 50px; \"><div class=\"row-bg-wrap\" data-bg-animation=\"none\" data-bg-animation-delay=\"\" data-bg-overlay=\"false\"><div class=\"inner-wrap row-bg-layer\" ><div class=\"row-bg viewport-desktop\"  style=\"\"><\/div><\/div><\/div><div class=\"row_col_wrap_12 col span_12 dark left\">\n\t<div  class=\"vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone\"  data-padding-pos=\"all\" data-has-bg-color=\"false\" data-bg-color=\"\" data-bg-opacity=\"1\" data-animation=\"\" data-delay=\"0\" >\n\t\t<div class=\"vc_column-inner\" >\n\t\t\t<div class=\"wpb_wrapper\">\n\t\t\t\t<div class=\"vc_separator wpb_content_element vc_separator_align_center vc_sep_width_100 vc_sep_border_width_5 vc_sep_pos_align_center vc_sep_color_grey wpb_content_element vc_separator-has-text\" ><span class=\"vc_sep_holder vc_sep_holder_l\"><span class=\"vc_sep_line\"><\/span><\/span><h4>Author<\/h4><span class=\"vc_sep_holder vc_sep_holder_r\"><span class=\"vc_sep_line\"><\/span><\/span>\n<\/div>\n<div class=\"wpb_text_column wpb_content_element\" >\n\t<p style=\"font-weight: 400;\"><strong>Malin Fromme, Christina Schrader and Pavel Strnad for the Alpha1 liver team from Aachen, as published in <a href=\"https:\/\/alpha1-deutschland.org\/en\/alpha1-journal\/\">Alpha1 Journal 2\/2024<\/a>.<\/strong><\/p>\n<\/div>\n\n\n\n<div class=\"divider-wrap\" data-alignment=\"default\"><div style=\"margin-top: 25px; height: 5px; margin-bottom: 25px;\" data-width=\"100%\" data-animate=\"\" data-animation-delay=\"\" data-color=\"default\" class=\"divider-border\"><\/div><\/div>\n<div class=\"wpb_text_column wpb_content_element\" >\n\t<p>Dear Alphas,<\/p>\n<p>Over the past few years, we have performed liver examinations on many of you, and most of you have also been contacted by phone or mail recently to fill out a questionnaire with us.<\/p>\n<p>The aim was to monitor the progression of alpha-1 antitrypsin deficiency (AATD)-associated liver and lung disease and to evaluate how well our non-invasive liver fibrosis tests (such as FibroScan) can predict the development of life-threatening liver disease (e.g., transplantation or decompensation of liver cirrhosis). The corresponding results have now been published in the journal Gastroenterology.<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39414159\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39414159\/<\/a><\/p>\n<p>In this study, 737 participants with the homozygous genotype Pi*ZZ were followed for an average of 3.5 years; 25 European centers participated. A total of 39 participants died, with liver and lung disease being the main causes of death. Among the 41 individuals who developed life-threatening liver disease, it was shown that they had already exhibited significantly higher non-invasive liver fibrosis test results at the initial baseline examination.<\/p>\n<p>Encouragingly, our liver fibrosis tests (e.g., FibroScan and AST-to-platelet index\/APRI) also demonstrated excellent predictive power for these liver endpoints. Not a single patient with an initial FibroScan value below 7.1 kPa developed life-threatening liver disease during the entire follow-up period, whereas the risk increased with rising liver stiffness. In contrast to our non-invasive liver fibrosis tests, surrogate markers of lung function (e.g., FEV1) showed only moderate predictive power for lung endpoints (such as transplantation or lung-related death).<\/p>\n<p>Overall, these results help us to better assess the individual risk of AATM-associated liver and lung disease and to perform accurate risk stratification. This is essential not only for clinical care but also for ongoing drug trials to enable tailored treatment.<\/p>\n<p>Another longitudinal project currently being conducted by the Alpha1 Liver Center in Aachen is a metabolic study evaluating the significance of metabolic risk factors, such as obesity and diabetes mellitus, in patients with the Pi*ZZ genotype. While finalization and publication of the results are still underway, preliminary analyses show clear findings. The presence of diabetes mellitus was associated with an approximately sixfold increased risk of developing life-threatening liver disease. Similar trends are also evident in Pi*ZZ patients with obesity \u2013 the risk in these patients was about four times higher than in patients of normal weight. These results underscore once again the importance of a healthy lifestyle with a balanced diet and sufficient exercise for liver health. At the same time, they indicate that patients with additional risk factors require closer monitoring.<\/p>\n<p>We would like to express our sincere gratitude for your cooperation and participation in the study. Without you, this study, which provides us with such important results for the management of &quot;alphas&quot; in the clinic and contributes to continuously improving care, would not have been possible! THANK YOU VERY MUCH! Please feel free to contact us if you have any further questions.<\/p>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>","protected":false},"excerpt":{"rendered":"Authors Malin Fromme, Christina Schrader, and Pavel Strnad for the Alpha1 Liver Team from Aachen, as published in the Alpha1 Journal 2\/2024. Dear Alphas, over the past few years, we have seen many of you...","protected":false},"author":1,"featured_media":6590,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,39,24],"tags":[],"class_list":["post-6589","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allgemein","category-alpha-1-leber","category-alpha1-journal"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Studie: Leberbeteiligung bei Alpha-1 besser vorhersagbar<\/title>\n<meta name=\"description\" content=\"Neue Studie zeigt: Nicht-invasive Tests wie FibroScan sagen lebensbedrohliche Lebererkrankungen bei Alpha-1-Betroffenen zuverl\u00e4ssig voraus.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/alpha1-deutschland.org\/en\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Studie: Leberbeteiligung bei Alpha-1 besser vorhersagbar\" \/>\n<meta property=\"og:description\" content=\"Neue Studie zeigt: Nicht-invasive Tests wie FibroScan sagen lebensbedrohliche Lebererkrankungen bei Alpha-1-Betroffenen zuverl\u00e4ssig voraus.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/alpha1-deutschland.org\/en\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel\/\" \/>\n<meta property=\"og:site_name\" content=\"Ihr Online Portal f\u00fcr Mitglieder und Interessierte\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-09T11:07:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-28T10:29:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/Leber-DNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Redaktion Alpha1 Deutschland e.V.\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Redaktion Alpha1 Deutschland e.V.\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel\"},\"author\":{\"name\":\"Redaktion Alpha1 Deutschland e.V.\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#\\\/schema\\\/person\\\/bbeaebe048b6117849fb55f50616d631\"},\"headline\":\"Neue Studie zur Leberbeteiligung beim Alpha1- Antitrypsin-Mangel ver\u00f6ffentlicht\",\"datePublished\":\"2024-11-09T11:07:50+00:00\",\"dateModified\":\"2025-04-28T10:29:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel\"},\"wordCount\":718,\"image\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/alpha1-deutschland.org\\\/wp-content\\\/uploads\\\/Leber-DNA.jpg\",\"articleSection\":[\"Allgemein\",\"Alpha-1 &amp; Leber\",\"Alpha1-Journal\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel\",\"url\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel\",\"name\":\"Studie: Leberbeteiligung bei Alpha-1 besser vorhersagbar\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/alpha1-deutschland.org\\\/wp-content\\\/uploads\\\/Leber-DNA.jpg\",\"datePublished\":\"2024-11-09T11:07:50+00:00\",\"dateModified\":\"2025-04-28T10:29:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#\\\/schema\\\/person\\\/bbeaebe048b6117849fb55f50616d631\"},\"description\":\"Neue Studie zeigt: Nicht-invasive Tests wie FibroScan sagen lebensbedrohliche Lebererkrankungen bei Alpha-1-Betroffenen zuverl\u00e4ssig voraus.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#primaryimage\",\"url\":\"https:\\\/\\\/alpha1-deutschland.org\\\/wp-content\\\/uploads\\\/Leber-DNA.jpg\",\"contentUrl\":\"https:\\\/\\\/alpha1-deutschland.org\\\/wp-content\\\/uploads\\\/Leber-DNA.jpg\",\"width\":1920,\"height\":1080,\"caption\":\"Schematische Darstellung einer Leber und eines DNA-Strangs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/alpha1-deutschland.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neue Studie zur Leberbeteiligung beim Alpha1- Antitrypsin-Mangel ver\u00f6ffentlicht\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#website\",\"url\":\"https:\\\/\\\/alpha1-deutschland.org\\\/\",\"name\":\"Ihr Online Portal f\u00fcr Mitglieder und Interessierte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/alpha1-deutschland.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/alpha1-deutschland.org\\\/#\\\/schema\\\/person\\\/bbeaebe048b6117849fb55f50616d631\",\"name\":\"Redaktion Alpha1 Deutschland e.V.\",\"sameAs\":[\"https:\\\/\\\/alpha1-deutschland.org\\\/\",\"https:\\\/\\\/www.instagram.com\\\/alpha1deutschland\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/marion-wilkens-1b71b6a4\\\/?originalSubdomain=de\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCkcwpGZWn3cQIXp931xMqbA\"],\"url\":\"https:\\\/\\\/alpha1-deutschland.org\\\/en\\\/author\\\/admin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Study: Liver involvement in Alpha-1 is more predictable","description":"New study shows: Non-invasive tests such as FibroScan reliably predict life-threatening liver diseases in Alpha-1 affected individuals.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/alpha1-deutschland.org\/en\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel\/","og_locale":"en_GB","og_type":"article","og_title":"Studie: Leberbeteiligung bei Alpha-1 besser vorhersagbar","og_description":"Neue Studie zeigt: Nicht-invasive Tests wie FibroScan sagen lebensbedrohliche Lebererkrankungen bei Alpha-1-Betroffenen zuverl\u00e4ssig voraus.","og_url":"https:\/\/alpha1-deutschland.org\/en\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel\/","og_site_name":"Ihr Online Portal f\u00fcr Mitglieder und Interessierte","article_published_time":"2024-11-09T11:07:50+00:00","article_modified_time":"2025-04-28T10:29:09+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/Leber-DNA.jpg","type":"image\/jpeg"}],"author":"Redaktion Alpha1 Deutschland e.V.","twitter_misc":{"Written by":"Redaktion Alpha1 Deutschland e.V.","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#article","isPartOf":{"@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel"},"author":{"name":"Redaktion Alpha1 Deutschland e.V.","@id":"https:\/\/alpha1-deutschland.org\/#\/schema\/person\/bbeaebe048b6117849fb55f50616d631"},"headline":"Neue Studie zur Leberbeteiligung beim Alpha1- Antitrypsin-Mangel ver\u00f6ffentlicht","datePublished":"2024-11-09T11:07:50+00:00","dateModified":"2025-04-28T10:29:09+00:00","mainEntityOfPage":{"@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel"},"wordCount":718,"image":{"@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#primaryimage"},"thumbnailUrl":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/Leber-DNA.jpg","articleSection":["Allgemein","Alpha-1 &amp; Leber","Alpha1-Journal"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel","url":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel","name":"Study: Liver involvement in Alpha-1 is more predictable","isPartOf":{"@id":"https:\/\/alpha1-deutschland.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#primaryimage"},"image":{"@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#primaryimage"},"thumbnailUrl":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/Leber-DNA.jpg","datePublished":"2024-11-09T11:07:50+00:00","dateModified":"2025-04-28T10:29:09+00:00","author":{"@id":"https:\/\/alpha1-deutschland.org\/#\/schema\/person\/bbeaebe048b6117849fb55f50616d631"},"description":"New study shows: Non-invasive tests such as FibroScan reliably predict life-threatening liver diseases in Alpha-1 affected individuals.","breadcrumb":{"@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#primaryimage","url":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/Leber-DNA.jpg","contentUrl":"https:\/\/alpha1-deutschland.org\/wp-content\/uploads\/Leber-DNA.jpg","width":1920,"height":1080,"caption":"Schematische Darstellung einer Leber und eines DNA-Strangs"},{"@type":"BreadcrumbList","@id":"https:\/\/alpha1-deutschland.org\/neue-studie-zur-leberbeteiligung-beim-alpha1-antitrypsin-mangel#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/alpha1-deutschland.org\/"},{"@type":"ListItem","position":2,"name":"Neue Studie zur Leberbeteiligung beim Alpha1- Antitrypsin-Mangel ver\u00f6ffentlicht"}]},{"@type":"WebSite","@id":"https:\/\/alpha1-deutschland.org\/#website","url":"https:\/\/alpha1-deutschland.org\/","name":"Your online portal for members and interested parties","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/alpha1-deutschland.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/alpha1-deutschland.org\/#\/schema\/person\/bbeaebe048b6117849fb55f50616d631","name":"Editorial team Alpha1 Germany eV.","sameAs":["https:\/\/alpha1-deutschland.org\/","https:\/\/www.instagram.com\/alpha1deutschland\/","https:\/\/www.linkedin.com\/in\/marion-wilkens-1b71b6a4\/?originalSubdomain=de","https:\/\/www.youtube.com\/channel\/UCkcwpGZWn3cQIXp931xMqbA"],"url":"https:\/\/alpha1-deutschland.org\/en\/author\/admin"}]}},"_links":{"self":[{"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/posts\/6589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/comments?post=6589"}],"version-history":[{"count":0,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/posts\/6589\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/media\/6590"}],"wp:attachment":[{"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/media?parent=6589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/categories?post=6589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alpha1-deutschland.org\/en\/wp-json\/wp\/v2\/tags?post=6589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}